Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs CarMax, Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while CarMax, Inc trades at $58.38 (market cap $8.26B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock and CarMax, Inc are close in size by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| BIO | KMX | |
|---|---|---|
Market Cap | $9.43B | $8.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $62.17 |
52-Week Low | $241.71 | $30.88 |
Enterprise Value | $9.18B | $26.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
CarMax (KMX) trades at $58.78, up 1.03% today, with a bullish technical signal and strong analyst support. Recent earnings have beaten expectations, with Q3 2025 and Q1 2026 EPS surpassing estimates, though Q2 2025 missed. Revenue remains stable around $26.4 billion, but net income margin is thin at 0.84%. The stock is near its consensus price target of $53.09, with a high target of $66.00. Positive news includes a Zacks Strong Buy rating and partnerships to enhance customer experience.
The outlook for KMX is cautiously optimistic, driven by earnings beats and bullish technicals, but high debt and margin pressures pose risks. Investment opportunity lies in continued execution and market share gains, while risks include competitive pressures and economic sensitivity. Analyst consensus leans Hold, with 68.58% holding, suggesting a wait-and-see approach for further growth confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
